BioSpace News Archive

C4X Discovery Holdings plc is pleased to note the announcement that Altasciences has been selected by Indivior PLC to conduct “A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 Under Fasting and Fed Conditions in Healthy Volunteers”.

AQILION AB is selling its entire stake in the portfolio company Glactone Pharma AB to Daniel Lifveredson Invest AB.

To help kick off the holiday season, BioSpace gave this Christmas classic a unique biopharma spin.

Similar to the Biotech Bay list, BioSpace takes a look at the top 10 2019 Life Sciences Ideal Employer Report’s for Genetown.

Scilligence, an innovation leader of unified informatics platform for biologics and small molecules drug R&D, has partnered with Certara to enable advanced data analysis and visualization capabilities.

Blood tests to be used to read entire genetic code of people attending a GP surgery, to look for faulty genes relating to cancer and heart disease

Under the terms of the deal, Scripps will run preclinical R&D, and in some cases, Phase I clinical trials. AbbVie will have an exclusive option to continue development and possible commercialization activities.

AstraZeneca released new data that shows Calquence as a monotherapy and combined with Roche’s anti-CD20 drug Gazyva significantly improved progression-free survival in previously untreated CLL.

Seqirus released new data that shows Fluad, an adjuvanted trivalent influenza vaccine, was more effective than standard non-adjuvanted trivalent influenza vaccine in reducing the risk of flu- and pneumonia-related hospitalization in patients 65-years-of-age and older.

The primary efficacy endpoint was change in best corrected visual acuity (BCVA) at 16 weeks compared to sham (placebo) treatment.